R&D News | pharmaphorum

News

'Inadvertent' leak teases survival benefit for Roche's TIGIT

In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir

News

Leo builds dermatology pipeline with Timber deal

Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.

News

FDA places Gilead's CD47 drug on another clinical hold

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi

News

Genesis raises $200m for AI drug discovery engine

Investor interest in artificial intelligence-powered drug discovery shows little signs of wearing off, as start-up Genesis Therapeutics rakes in an impressive $200 million

News

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe

News

OneOncology taps Verily for clinical trials platform

OneOncology has joined forces with Verily to speed up and improve the efficiency of clinical trials run through its network of independent cancer treatment centres in the

'Inadvertent' leak teases survival benefit for Roche's TIGIT

Leo builds dermatology pipeline with Timber deal

FDA places Gilead's CD47 drug on another clinical hold

Genesis raises $200m for AI drug discovery engine

Trial backs use of Cabometyx, Tecentriq in prostate cancer

OneOncology taps Verily for clinical trials platform

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks